{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '9.', 'STATISTICS', '123', '9.1', 'Determination of Sample Size', '123', '9.2', 'Data to be Analyzed', '123', '9.3', 'Analysis Populations', '123', '9.4', 'Statistical Methods', '124', '9.4.1', 'Definition of Baseline', '125', '9.4.2', 'Disposition of Study Subjects', '126', '9.4.3', 'Demography and Baseline Characteristics', '126', '9.4.4', 'Prior and Concomitant Medications', '126', '9.4.5', 'Exposure and Compliance', '127', '9.4.6', 'Safety Analyses', '127', '9.4.6.1', 'Adverse Events', '128', '9.4.6.2', 'Other Safety Analyses', '132', '9.4.7', 'Analysis of Efficacy Endpoints', '133', '9.4.8', 'Handling of Missing Data', '134', '9.4.9', 'Pharmacokinetic/Pharmacodynamic Correlations', '134', '9.4.10', 'Immunogenicity', '134', '9.5', 'Subgroup Analysis', '135', '9.6', 'Safety Monitoring Committees', '135', '9.7', 'Interim Analysis', '135', '10.', 'ETHICS', '136', '10.1', 'Institutional Review Board/Independent Ethics Committee', '136', '10.2', 'Ethical Conduct of the Study', '136', '10.3', 'Subject Information and Informed Consent', '137', '10.4', 'Subject Data Protection', '137', '11.', 'STUDY ADMINISTRATION', '138', '11.1', 'Administrative Structure', '138', '11.2', 'Study and Study Site Closure', '138', '11.3', 'Study Discontinuation', '138', '11.4', 'Data Handling and Record Keeping', '139', '11.5', 'Direct Access to Source Data/Documents', '139', '11.6', 'Investigator Information', '140', '11.6.1', 'Investigator Obligations', '140', '11.6.2', 'Protocol Signatures', '141', '11.6.3', 'Publication Policy', '141', '11.7', 'Financing and Insurance', '141', '12.', 'REFERENCES', '142', '13.', 'APPENDICES', '144', '13.1', 'Appendix 1: Methotrexate Dose Reduction Guidelines', '145', 'Amendment 2: 06 March 2019', '15', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '13.2', 'Appendix 2: Tuberculosis Risk Questionnaire', '147', '13.3', 'Appendix 3: Clinical Criteria for Diagnosing Anaphylaxis', '150', '13.4', 'Appendix 4: Recommendations for Management of Latent', 'Tuberculosis Infection', '151', '13.5', 'Appendix 5: Protocol Amendment 2 Summary of Changes', '152', 'Amendment 2: 06 March 2019', '16', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'LIST OF TABLES', 'Table 1', 'CL04041024 (CREDO 4) Schedule of Events (Open-Label', 'Treatment Period and Safety Follow-Up Period)', '46', 'Table 2', 'Components and Composition of OKZ (CDP6038; L04041) Drug', 'Product', '76', 'Table 3', 'Prohibited Medications', '85', 'Table 4', 'CTCAE Grades and Corresponding AE Severity', '98', 'Table 5', 'List of Endemic TB Countries (Incidence >50/100,000)', '148', 'LIST OF FIGURES', 'Figure 1', 'CL04041024 (CREDO 4 4) Study Schematic', '45', 'Amendment 2: 06 March 2019', '17', 'Confidential']\n\n###\n\n", "completion": "END"}